GENECAST is a company specialized in ctDNA liquid biopsy.
Our outstanding detection sensitivity
Improves cancer management systems,
Gives more cancer treatment options,
Higher the success rate of targeted therapy development.
And finally, an early cancer diagnosis will be feasible.
This is why GENECAST is dedicated to
The higher detection sensitivity of liquid biopsy.
Our technology takes you one step closer to accurately analyze the cause of cancer.
GENECAST’s ADPS™ selectively amplifies mutant genes only while leaving wild-type intact.
Analyzing EGFR mutations, the most common mutations in non-small cell lung cancer (NSCLC) with up to 0.01% detection sensitivity.
GENECAST’s ADPS™ let you directly face the causes of cancer.
Precise analysis of circulating tumor DNA (ctDNA) with us.
Recommends more extended and appropriate treatment options to clinicians.
In the end, it makes cancer a manageable disease.
by Providing an accurate diagnosis, prognosis, prescription,
and recurrence monitoring, and precision medicine,
GENECAST supports you in the fight against cancer